Wedbush Reaffirms Outperform Rating for Aerovate Therapeutics (NASDAQ:AVTE)
Aerovate Therapeutics (NASDAQ:AVTE – Get Free Report)‘s stock had its “outperform” rating restated by equities researchers at Wedbush in a report released on Tuesday, Benzinga reports. They currently have a $41.00 target price on the stock. Wedbush’s target price points to a potential upside of 95.15% from the stock’s current price. Wedbush also issued estimates […]
More Stories
Innovator Premium Income 10 Barrier ETF – January (NYSEARCA:JAND) to Issue $0.49 Dividend
Innovator Premium Income 10 Barrier ETF – January (NYSEARCA:JAND – Get Free Report) declared a dividend on Friday, September 27th,...
AppTech Payments Corp. (NASDAQ:APCX) Short Interest Down 23.1% in September
AppTech Payments Corp. (NASDAQ:APCX – Get Free Report) saw a significant decrease in short interest in the month of September....
Short Interest in Dollar Tree, Inc. (NASDAQ:DLTR) Increases By 49.7%
Dollar Tree, Inc. (NASDAQ:DLTR – Get Free Report) was the target of a significant increase in short interest in September....
Short Interest in Davis Commodities Limited (NASDAQ:DTCK) Rises By 49.1%
Davis Commodities Limited (NASDAQ:DTCK – Get Free Report) was the target of a large growth in short interest in the...
B3 S.A. – Brasil, Bolsa, Balcão (OTC:BOLSY) to Issue Dividend of $0.02
B3 S.A. – Brasil, Bolsa, Balcão (OTC:BOLSY – Get Free Report) announced a dividend on Friday, September 20th, NASDAQ reports....
Mullen Group Ltd. to Issue Monthly Dividend of $0.07 (TSE:MTL)
Mullen Group Ltd. (TSE:MTL – Get Free Report) announced a monthly dividend on Friday, September 20th, Zacks reports. Shareholders of...